Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Pariente
Edouard Louis

Showing results (241-250 of 364) with videos related to

Pageof 37
Sort By:
Gastroenterology|February 26, 2026
The effect of dose-intensification after secondary loss of response to ustekinumab in Crohn's disease: Results of the REScUE studyPeter Bossuyt, Jean-Francois Rahier, Filip Baert, et al.
Journal of Crohn'S & Colitis|April 9, 2013
Optimising monitoring in the management of Crohn's disease: a physician's perspectivePavol Papay, Ana Ignjatovic, Konstantinos Karmiris, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 4, 2020
Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's DiseasePeter Bossuyt, Erwin Dreesen, Jordi Rimola, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 3, 2019
Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn's DiseaseNassim Hammoudi, Dominique Cazals-Hatem, Claire Auzolle, et al.
BMJ Open Gastroenterology|February 15, 2022
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitisEdouard Louis, Kristine Paridaens, Sameer Al Awadhi, et al.
Intestinal Research|April 15, 2022
The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitisJae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, et al.
Gastroenterology|July 10, 2002
NOD2/CARD15 does not influence response to infliximab in Crohn's diseaseSeverine Vermeire, Edouard Louis, Paul Rutgeerts, et al.
Journal of Crohn'S & Colitis|November 2, 2024
Impact of Histological Remission for Predicting Clinical Relapse in Crohn's Disease: A Post Hoc Analysis of the Prospective STORI CohortCatherine Reenaers, Diana Enea, Marie Nachury, et al.
Journal of Crohn'S & Colitis|June 2, 2021
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension StudyMarc Ferrante, Brian G Feagan, Julián Panés, et al.
Scandinavian Journal of Gastroenterology|December 21, 2021
Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitisAxel U Dignass, Kristine Paridaens, Sameer Al Awadhi, et al.
Pageof 37

Showing results (241-250 of 364) with videos related to

Sort By:
Pageof 37
Gastroenterology|February 26, 2026
The effect of dose-intensification after secondary loss of response to ustekinumab in Crohn's disease: Results of the REScUE studyPeter Bossuyt, Jean-Francois Rahier, Filip Baert, et al.
Journal of Crohn'S & Colitis|April 9, 2013
Optimising monitoring in the management of Crohn's disease: a physician's perspectivePavol Papay, Ana Ignjatovic, Konstantinos Karmiris, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 4, 2020
Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's DiseasePeter Bossuyt, Erwin Dreesen, Jordi Rimola, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 3, 2019
Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn's DiseaseNassim Hammoudi, Dominique Cazals-Hatem, Claire Auzolle, et al.
BMJ Open Gastroenterology|February 15, 2022
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitisEdouard Louis, Kristine Paridaens, Sameer Al Awadhi, et al.
Intestinal Research|April 15, 2022
The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitisJae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, et al.
Gastroenterology|July 10, 2002
NOD2/CARD15 does not influence response to infliximab in Crohn's diseaseSeverine Vermeire, Edouard Louis, Paul Rutgeerts, et al.
Journal of Crohn'S & Colitis|November 2, 2024
Impact of Histological Remission for Predicting Clinical Relapse in Crohn's Disease: A Post Hoc Analysis of the Prospective STORI CohortCatherine Reenaers, Diana Enea, Marie Nachury, et al.
Journal of Crohn'S & Colitis|June 2, 2021
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension StudyMarc Ferrante, Brian G Feagan, Julián Panés, et al.
Scandinavian Journal of Gastroenterology|December 21, 2021
Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitisAxel U Dignass, Kristine Paridaens, Sameer Al Awadhi, et al.
Pageof 37